---

title: "Urinary Peptidomic Profiling in Post-Acute Sequelae of SARS-CoV-2 Infection: A Case-Control Study"
tags:
- âž• 2025-12-25
- ðŸ§ª Biomarker
created: '2025-10-17'
published: '2025-10-17'

---


<details>
<summary>GÃ¼lmez et al. (2025)</summary>

- **Authors:** Dilara GÃ¼lmez, Justyna Siwy, Katharina Kurz, Ralph Wendt, Miroslaw Banasik, BjÃ¶rn Peters, Emmanuel Dudoignon, Francois Depret, Mercedes Salgueira, Elena Nowacki, Amelie Kurnikowski, Sebastian Mussnig, Simon Krenn, Samuel Gonos, Judith LÃ¶ffler-Ragg, GÃ¼nter Weiss, Harald Mischak, Manfred Hecking, Eva Schernhammer, Joachim Beige, and UriCoV working group 
- **Institutes:** Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria; Mosaiques Diagnostics GmbH, Hannover, Germany; Department of Internal Medicine II (Infectious Diseases, Immunology, Rheumatology, Pneumology), Medical University of Innsbruck, Innsbruck, Austria; Division of Nephrology, St. Georg Hospital, Leipzig, Germany; Department of Nephrology, Transplantation Medicine and Internal Diseases, WrocÅ‚aw Medical University, Wroclaw, Poland; Department of Molecular and Clinical Medicine, Institute of Medicine, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Region VÃ¤stra GÃ¶taland, Skaraborg Hospital, Department of Nephrology, SkÃ¶vde, Sweden; Department of Anaesthesiology and Critical Care, HÃ´pital Saint Louis - LariboisiÃ¨re, AP-HP, 75010, Universite Paris CitÃ©, INSERM UMR-S 942 MASCOT, Paris, France; Virgen Macarena Hospital, University of Seville, 41009 Seville, Spain; UniversitÃ© des Patients - Sorbonne UniversitÃ©, 75013 Paris, France; IUVABIT e.U., Analytics & Data Science, Vienna, Austria; Department of Nephrology, Medical University of Vienna, Vienna, Austria; Kuratorium for Dialysis and Transplantation (KfH) Leipzig, Leipzig, Germany; Department of Internal Medicine II, Martin-Luther-University Halle-Wittenberg, Halle, Germany 
- **Publisher:** medRxiv 
- **Link:** [DOI](https://doi.org/10.1101/2025.10.15.25338065)

</details>


## Summary

This study identified a potential biomarker for PASC (Long Covid) by analyzing 195 different peptides in urine. This "PASC195" signature, which is heavily linked to collagen dysregulation, was able to successfully distinguish PASC patients from both healthy people and, notably, from patients with non-COVID-19 ME/CFS. This finding suggests that while PASC and ME/CFS share symptoms, their underlying molecular profiles may be different, which is a critical step for developing specific diagnostic tests. The discovery of this urinary signature provides a non-invasive tool that could, after much more research, complement or replace subjective symptom-based diagnosis. The study's computational analysis also pointed to existing drug classes (GLP-1 RA ðŸ’Š and MRA ðŸ’Š) as potential treatments, offering a new direction for future clinical trials. However, the authors' inability to validate this signature in a second, different cohort highlights that the biomarker is not yet ready for clinical use and requires significant further validation.

## What was researched?

This study researched whether analyzing peptides (small protein fragments) in urine, a process called urinary peptidomics, could be used to develop a non-invasive diagnostic test for Post-acute sequelae of SARS-CoV-2 infection (PASC).

## Why was it researched?

Currently, diagnosing PASC relies on symptom-based criteria, which can be uncertain and subjective. The researchers hypothesized that analyzing urinary peptides could provide a more objective, non-invasive way to diagnose PASC and offer new insights into its underlying disease mechanisms, which remain unclear.

## How was it researched?

This was a case-control study that used capillary electrophoresis-mass spectrometry (CE-MS) to analyze urine samples from 50 PASC patients (approximately 10 months post-infection) and 50 controls. The control group included 42 healthy individuals and 8 patients with non-COVID-19-associated myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The researchers used a machine learning model (support vector machine) to identify significant differences in peptide abundance and build a diagnostic classifier from a training set (n=60), which was then tested on a separate validation set (n=40).

## What has been found?

The researchers identified a unique signature of 195 urinary peptides, named **PASC195**, that was significantly different in PASC patients compared to controls. This signature, characterized mainly by a predominant abundance of collagen alpha chains, was able to effectively distinguish PASC cases from both healthy controls and non-COVID-19 ME/CFS patients with high accuracy (AUC of 0.962) in the validation set. The identified peptides suggest PASC involves dysregulated collagen, ongoing inflammation, and endothelial damage. A computational (in silico) analysis also suggested that GLP-1 RA ðŸ’Š and MRA ðŸ’Š (mineralocorticoid receptor antagonists) might be potentially beneficial interventions.

## Discussion

The authors note that the PASC195 classifier could not be validated in a separate, independent cohort (UriCoV), which limits the generalizability of the findings. They suggest this was likely due to differences in cohort selection, how "cases" were defined (clinician-diagnosed vs. self-reported), and the timing of sample collection (10 months vs. 3 years post-infection). The study was also limited by its small sample size, which prevented subgroup analyses (e.g., by sex or age).

## Conclusion & Future Work

The authors conclude that they have identified a promising, non-invasive urinary peptide signature (PASC195) that could potentially advance PASC diagnostics. They state that this signature reflects the underlying molecular pathophysiology of PASC. Future longitudinal studies with larger, more diverse cohorts are needed to confirm these findings and validate the biomarker.
